Literature DB >> 11217141

Central role of the adipocyte in the metabolic syndrome.

R N Bergman1, G W Van Citters, S D Mittelman, M K Dea, M Hamilton-Wessler, S P Kim, M Ellmerer.   

Abstract

Insulin resistance is associated with a plethora of chronic illnesses, including Type 2 diabetes, dyslipidemia, clotting dysfunction, and colon cancer. The relationship between obesity and insulin resistance is well established, and an increase in obesity in Western countries is implicated in increased incidence of diabetes and other diseases. Central, or visceral, adiposity has been particularly associated with insulin resistance; however, the mechanisms responsible for this association are unclear. Our laboratory has been studying the physiological mechanisms relating visceral adiposity and insulin resistance. Moderate fat feeding of the dog yields a model reminiscent of the metabolic syndrome, including visceral adiposity, hyperinsulinemia, and insulin resistance. We propose that insulin resistance of the liver derives from a relative increase in the delivery of free fatty acids (FFA) from the omental fat depot to the liver (via the portal vein). Increased delivery results from 1) more stored lipids in omental depot, 2) severe insulin resistance of the central fat depot, and 3) possible regulation of visceral lipolysis by the central nervous system. The significance of portal FFA delivery results from the importance of FFA in the control of liver glucose production. Insulin regulates liver glucose output primarily via control of adipocyte lipolysis. Thus, because FFA regulate the liver, it is expected that visceral adiposity will enhance delivery of FFA to the liver and make the liver relatively insulin resistant. It is of interest how the intact organism compensates for insulin resistance secondary to visceral fat deposition. While part of the compensation is enhanced B-cell sensitivity to glucose, an equally important component is reduced liver insulin clearance, which allows for a greater fraction of B-cell insulin secretion to bypass liver degradation, to enter the systemic circulation, and to result in hyperinsulinemic compensation. The signal(s) resulting in B-cell up-regulation and reduced liver insulin clearance with visceral adiposity is (are) unknown, but it appears that the glucagon-like peptide (GLP-1) hormone plays an important role. The integrated response of the organism to central adiposity is complex, involving several organs and tissue beds. An investigation into the integrated response may help to explain the features of the metabolic syndrome.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11217141     DOI: 10.2310/6650.2001.34108

Source DB:  PubMed          Journal:  J Investig Med        ISSN: 1081-5589            Impact factor:   2.895


  43 in total

1.  Intravenous estrogens increase insulin clearance and action in postmenopausal women.

Authors:  R E Van Pelt; W S Gozansky; R S Schwartz; W M Kohrt
Journal:  Am J Physiol Endocrinol Metab       Date:  2003-04-08       Impact factor: 4.310

2.  Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production.

Authors:  Michael W Rajala; Silvana Obici; Philipp E Scherer; Luciano Rossetti
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

3.  Glut4 storage vesicles without Glut4: transcriptional regulation of insulin-dependent vesicular traffic.

Authors:  Danielle N Gross; Stephen R Farmer; Paul F Pilch
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

Review 4.  The omentum: anatomical, metabolic, and surgical aspects.

Authors:  Danielle Collins; Aisling M Hogan; Donal O'Shea; Des C Winter
Journal:  J Gastrointest Surg       Date:  2009-03-17       Impact factor: 3.452

5.  Renin-angiotensin-aldosterone system in insulin resistance and metabolic syndrome.

Authors:  Undurti N Das
Journal:  J Transl Int Med       Date:  2016-07-07

6.  The effect of hesperidin supplementation on metabolic profiles in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled clinical trial.

Authors:  Zahra Yari; Mina Movahedian; Hossein Imani; Seyed Moayed Alavian; Mehdi Hedayati; Azita Hekmatdoost
Journal:  Eur J Nutr       Date:  2019-12-16       Impact factor: 5.614

Review 7.  Dietary fats and diabetes mellitus: is there a good fat?

Authors:  C J Segal-Isaacson; E Carello; J Wylie-Rosett
Journal:  Curr Diab Rep       Date:  2001-10       Impact factor: 4.810

8.  Burst-like control of lipolysis by the sympathetic nervous system in vivo.

Authors:  Katrin Hücking; Marianthe Hamilton-Wessler; Martin Ellmerer; Richard N Bergman
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

9.  Role of resistin in diet-induced hepatic insulin resistance.

Authors:  Evan D Muse; Silvana Obici; Sanjay Bhanot; Brett P Monia; Robert A McKay; Michael W Rajala; Philipp E Scherer; Luciano Rossetti
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

10.  Regulation of ATGL expression mediated by leptin in vitro in porcine adipocyte lipolysis.

Authors:  Yu-cheng Li; Xue-li Zheng; Bing-ting Liu; Gong-she Yang
Journal:  Mol Cell Biochem       Date:  2009-07-22       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.